Health Care [ 8/12 ] | Biotechnology [ 31/76 ]
NASDAQ | Common Stock
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 24, 26 | 12.27 Increased by +3.96 K% | -0.20 Increased by +6.12 K% |
| Nov 5, 25 | -3.54 Decreased by -326.51% | -0.35 Decreased by -903.12% |
| Jul 24, 25 | -1.58 Decreased by -1.23 K% | -0.23 Decreased by -592.07% |
| Apr 30, 25 | -2.45 Decreased by -275.00% | -0.18 Decreased by -1.26 K% |
| Feb 12, 25 | 0.30 Decreased by -87.35% | 0.28 Increased by +7.96% |
| Oct 31, 24 | -0.83 Decreased by -312.82% | -0.29 Decreased by -186.21% |
| Aug 1, 24 | 0.14 Increased by +75.00% | -0.04 Increased by +450.00% |
| May 2, 24 | 1.40 Increased by +263.45% | -0.13 Increased by +1.18 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 900.77 M Increased by +1.09 K% | 782.16 M Increased by +2.99 K% | Increased by +86.83% Increased by +159.03% |
| Sep 30, 25 | 71.16 M Increased by +18.90% | -202.11 M Decreased by -300.78% | Decreased by -284.02% Decreased by -237.07% |
| Jun 30, 25 | 65.29 M Decreased by -16.16% | -105.75 M Decreased by -1.28 K% | Decreased by -161.97% Decreased by -1.50 K% |
| Mar 31, 25 | 74.98 M Increased by +20.09% | -153.40 M Decreased by -270.03% | Decreased by -204.60% Decreased by -241.58% |
| Dec 31, 24 | 75.50 M Increased by +136.10% | 25.31 M Decreased by -83.94% | Increased by +33.52% Increased by +144.49% |
| Sep 30, 24 | 59.85 M Decreased by -50.14% | -50.43 M Decreased by -295.24% | Decreased by -84.26% Decreased by -491.55% |
| Jun 30, 24 | 77.87 M Decreased by -48.07% | 8.98 M Increased by +76.14% | Increased by +11.54% Increased by +239.18% |
| Mar 31, 24 | 62.43 M Increased by +6.59% | 90.22 M Increased by +288.76% | Increased by +144.51% Increased by +264.74% |